https://www.selleckchem.com/products/azd6738.html
Background The Pipeline Vantage Embolization Device with Shield Technology is a next generation flow diverter developed to improve aneurysm occlusion and implant endothelialization in addition to lowering thrombogenicity. We report here the in vivo biocompatibility and in vitro hemocompatibility performance of the Pipeline Vantage Embolization Device with Shield Technology (Vantage) compared with the Pipeline Flex Embolization Device (Flex). Methods Biocompatibility (via histology), aneurysm occlusion and vessel patency (via angiography
Like
Comment
Share
